Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major cause of blood infections.

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable effect for a drug ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

An experimental antidepressant in development at Gate Neurosciences has started a proof-of-concept study to see if its efficacy can be boosted by a digital neurocognitive training tool. The study ...

As World Cancer Day approached this year, the increasing focus on precision oncology continued apace. Here, Professor Marie-Laure Yaspo, Chief Scientific Officer at Alacris Theranostics, discusses ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

UK Health Secretary West Streeting has announced plans for a national strategy for men's health, tackling issues "affecting men of all ages that are costing lives." The aim is to address diseases ...

In the dynamic environment of biotechnology trials, the significance of Clinical Data Management systems (CDMs) cannot be overstated. As we navigate the complexities of these trials and the ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...